The FDA has approved a label expansion for once-weekly tirzepatide for adults with overweight and obesity, allowing the medication to be used with a pen that is equipped with four doses of the drug, ...

Phase 3 trial results show combined ixekizumab and tirzepatide therapy outperforms ixekizumab alone for patients with psoriasis and obesity or overweight.

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes medications — also known as GLP-1 and GIP injections — are changing the way we ...

Tirzepatide use is associated with a lower incidence of new or progressive diabetic retinopathy (DR) and fewer complications.

Less than a week after the U.S. Food & Drug Administration (FDA) determined that the shortage of the tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been “resolved” and ...

Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a ...

The skin over a mouse’s shoulders warmed up after a dozen days on tirzepatide. That heat map, taken with an infrared camera, pointed to a familiar patch of tissue between the shoulder blades: brown ...

Weight loss medications Mounjaro and Zepbound, which contain the active ingredient tirzepatide, may lower the risk of diabetic retinopathy.